Accelrys Materials Studio Enhances Modeling and Simulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Accelrys Materials Studio Enhances Modeling and Simulation

Equipment and Processing Report

Accelrys Materials Studio 7.0 modeling and simulation environment contains enhancements in quantum mechanics, classical simulation, usability, visualization, and collaboration to enable scientists to engineer better performing and more cost-effective materials. The software enables scientists to perform highly complex materials research using multi-scale simulation methods to construct, manipulate, and view models of molecules, crystalline materials, surfaces, polymers, and mesoscale structures. An improved solubility-property prediction provides better understanding of solvation properties. By understanding and predicting the relationships between a material's atomic and molecular structure and its properties and behaviors, materials scientists can develop better performing materials of all types faster and more efficiently than with test and experimentation alone.

Source: Accelrys

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Equipment and Processing Report,
Click here